Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2013. The report details a specific share repurchase transaction executed on August 22, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 750,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,673.50 pence per share; lowest price paid was 1,655.00 pence per share.
- Treasury Holdings (Settled): 511,234,412 shares (9.44% of total issued share capital).
- Treasury Holdings (Including Unsettled): 513,402,412 shares (10.47% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,902,026,484 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 750,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.47% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Conduct Authority's Disclosure and Transparency Rules regarding share repurchases.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (511,234,412 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.47% held in Treasury including unsettled shares).
- Check the number of shares in issue (4,902,026,484) to ensure accurate denominator usage for disclosure thresholds under FCA rules.
- Note that this filing does not contain operational or financial performance data for the period.